VASO: Vaso Corporation Stock

SIC 3845 – Electromedical and Electrotherapeutic Apparatus

Valuation
Market Cap ($M) 40.41
Enterprise Value ($M) 14.15
Book Value ($M) 27.70
Book Value / Share 0.16
Price / Book 1.46
NCAV ($M) -4.05
NCAV / Share -0.02
Price / NCAV -9.98

Profitability (mra)
Return on Invested Capital (ROIC) 0.03
Return on Assets (ROA) 0.01
Return on Equity (ROE) 0.04

Liquidity (mrq)
Quick Ratio 1.45
Current Ratio 1.47

Balance Sheet (mrq) ($M)
Current Assets 51.19
Assets 82.94
Liabilities 55.24
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 86.77
Operating Income 0.28
Net Income 0.95
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 3.28
Cash from Investing 11.73
Cash from Financing -0.09

(click for more detail)
Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-31 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 ☐ Transition Report Pursuant t
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 ☐ Transition Report Pursuant to Sec
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 ☐ Transition Report Pursuant to Se

(click for more detail)

Similar Companies
UNVC – Univec, Inc. USAQ – QHSLab, Inc.
UTRS – Minerva Surgical, Inc. VICA – Rafina Innovations Inc.
VIVE – Viveve Medical, Inc.


Financial data and stock pages provided by
Fintel.io